Significant fluctuations in
Pfizer stocks have been witnessed lately. According to various reports, many investment companies, including Westbourne Investments, Glenview Trust co, Great Lakes Advisors, and Fred Alger Management, among others, have collectively decided to increase their stake in Pfizer, reflecting overall confidence. Meanwhile, some entities like UBS Asset Management Americas and Birmingham Capital Management Co. Inc. AL have reduced their Pfizer holdings. Despite these shifts, Pfizer has maintained a Consensus Rating of \"Hold\" from brokerages. A series of crucial patent litigation developments might alter Pfizer's bull case. Following the report linking COVID vaccine shots to child deaths,
Pfizer, Moderna, and BioNtech stocks significant fell. Pfizer's late-stage pipeline fuels long-term growth prospects are being eyed, suggesting Pfizer has some foundational strength. Alarmingly, the shares could get even cheaper next year. The firm constantly beat its earning estimates, and there are signs of a potential turnaround in the pharmaceutical stock. Despite an impressive Q2, more pipeline data is awaited. Pfizer Inc. also raised its guidance, and stock analysts increased their targets, even though the stock is still considered cheap.
Pfizer Stocks News Analytics from Tue, 29 Apr 2025 07:00:00 GMT to Sun, 14 Sep 2025 00:09:44 GMT -
Rating 2
- Innovation -1
- Information 8
- Rumor 3
